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A high-affinity subtype-selective agonist ligand for the thyroid 
hormone receptor 
Grazia Chiellinil, James W Aprilettl ‘*, Hikari Al Yoshiharal, John D Baxter*, 
Ralff CJ Ribeiro* and Thomas S ScanIan’ 
Background: Thyroid hormones regulate many different physiological 
processes in different tissues in vertebrates. Most of the actions of thyroid 
hormones are mediated by the thyroid hormone receptor (TR), which is a 
member of the nuclear receptor superfamily of ligand-activated transcription 
regulators. There are two different genes that encode two different TRs, TRa 
and TRP. and these two TRs are often co-expressed at different levels in 
different tissues. Most thyroid hormones do not discriminate between the two 
TRs and bind both with similar affinities. 
Results: We have designed and synthesized a thyroid hormone analog that has 
high affinity for the TRs and is selective in both binding and activation functions for 
TRP over TRa. The compound, GC-1, was initially designed to solve synthetic 
problems that limit thyroid hormone analog preparation, and contains several 
structural changes with respect to the natural hormone 3,5,3’-triiodo-L-thyronine 
(T,). These changes include replacement of the three iodines with methyl and 
isopropyl groups, replacement of the biaryl ether linkage with a methylene linkage, 
and replacement of the amino-acid sidechain with an oxyacetic-acid sidechain. 
Conclusions: The results of this study show that GC-1 is a member of a new 
class of thyromimetic compounds that are more synthetically accessible than 
traditional thyromimetics and have potentially useful receptor binding and 
activation properties. The TRP selectivity of GC-1 is particularly interesting and 
suggests that GC-1 might be a useful in viva probe for studying the 
physiological roles of the different thyroid hormone receptor isoforms. 
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Introduction 
‘I’hyoid hormones, of which 3,5,3’-triiodo-I,-thyronine 
(I‘,,, Figure 1) is the major active form, are important 
endocrine signaling molecules in vertebrates that exert a 
multitude of physiological effects [l]. These influences 
affect fetal de\ elopmcnt, lipid and carbohydrate metabo- 
lism, and cardio\,ascular, pulmonary and neuromuscular 
st:ltus. hlost of the physiological actions of T,; result from 
intlucnces on transcription of Ti-responsive genes that 
are mediated rhrough thyroid hormone receptors (TRs). 
‘I‘he TR is ;I member of a superfamily of nuclear ligand- 
rcgulared transcription factors that includes receptors for 
steroid hormones such as estrogens and glucocorticoids. 
3s well ;1s those, like rhe TR. that are regulated by nons- 
teroidal ligands such as the rctinoic acid and vitamin D 
receptors [S-j]. Nuclear receptor family members share ;I 
common domain organization that includes a central 
highI>- conserved DNA\-binding domain (DBD), a less 
conserved carboxy-terminal ligand-binding domain 
(LBD), and an amino-terminal domain that varies greatly 
in rerms of size and amino acid composition. Genes rcgu- 
larcd by ‘I’; contain 3 regulatory DNA sequence linked to 
their promoter called a th>-roid response clement (TRE). 
‘I’hc TR is localized in the nucleus and binds to the 
TRE, commonly as ;1 heterodimer \vith the retinoid X 
receptor (RXR) 131. In the absence of ‘r;, the ‘I’R-RXR 
heterodimer can repress gene transcriprion [h]. Acti\,a- 
tion of transcription occurs when T; permeates the 
nucleus and binds to the ‘1-R. Recent structural data on 
the liganded ‘I‘R LBD reveals a unique internal-binding 
mode for the hormone ligand ‘I’j; the hormone is com- 
pletely buried in the solvent occluded hydrophobic core 
of the LBD [7]. Thus, the hormone plays a structural role 
in transcriptional acti\-ation by correctly shaping an 
active conformation of the ‘I’R. The internal ligand- 
binding mode has also been obser\-ed for other nuclear 
receptors including the retinoic acid receptor (RAR) [8] 
and the estrogen receptor (ER) [CI] and is most likcl) 
general for the entire superfamily-. 
In vertebrates there are two different ‘1-R subtype gents, 
TRcr and ‘I‘RP [lo], which reside on chromosomes 17 and 
3, respectively. The polypcptide sequences of TRa and 
TRP are 82% identical in rhe LBD and 86% identical in 
the DBD. 1-R di\,ersit); is enhanced by the presence of 
additional isoforms from the CI and p genes. Altcrnati\,e 
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Figure 1 
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Agonist ligands for the thyroid hormone 
receptor. Thyroid hormone is 
3,5,3’-triiodo-L-thyronine (T,). DIMIT 
(dimethyl-isopropyl-T,), I, 2, and GC-1 are 
synthetic thyromimetic compounds. 
splicing of the most 3’ exon of the TRc(, gene gives rise to 
a non-‘1’3-binding isoform, TRcQ, that lacks the carboxy- 
terminal 40 amino acids of human TRcx, but contains an 
additional 120 amino acids compared to the human TRa,. 
Alternative usage of a 5’ exon in the TRP, gene gives rise 
to ‘I‘RB,, which is identical to TRB, except that it contains 
a unique amino-terminal domain. Both TR subtypes and 
the resulting isoforms are widely distributed, although 
there are differences in concentrations in various tissues 
[ 111. For example, TRa, and TRa, are most abundant in 
skeletal muscle and in brain, respectively, whereas the 
‘I’RP, is more homogeneously distributed but found in 
high levels in liver. kidney, and brain. In contrast, the 
TRPz is mostly restricted to the pituitary although its 
mRNA expression has been reported in other regions such 
as the hypothalamus and hippocampus [ 111. 
Several of the effects of thyroid hormones in excess might 
be beneficial in medical therapy. These include a lowering 
of the serum cholesterol levels, weight loss, and improve- 
ment in myocardial contractility [l]. These beneficial influ- 
ences are counterbalanced by deleterious effects, however. 
especially tachycardia and a tendency to develop atrial 
arrhythmias. It follows that a thyroid hormone analog that 
retained the beneficial influences of T3, but was devoid of 
the deleterious influences, such as on the heart rate, would 
be a useful agent for medical therapy. 
‘I’wo thyromimetic lead compounds (1 and 2, Figure 1) 
that can separate the liver and heart effects have been 
reported [ 1 L-16]. Interestingly, 2 sho1l.s selectivity for 
activation of TRP, compared to ‘I’Ra, [lb]. Such sclectiv- 
ity suggests an approach inv-olving the development of 
receptor-subtype-specific ligands because receptor 
subtype selectivity could correlate with tissue-specific in 
ei7;o thyromimctic effects. In this paper we describe the 
synthesis and no\-el properties of a TR analog (X-1 
(Figure l), which is a halogen-free high affinity ligand that 
is selective for TRP over TRCL 
Results 
Ligand design 
The initial goal of this research was to design a thyroid 
hormone analog that would be amenable to extensive 
analog production. There is a relatively large body of 
structure-activity data on thyroid hormone analogs that 
highlights required structural features for high-affinity ‘1-R 
Iigands [ 17,181. There are structural features of the natural 
hormone ‘1’,3 that present significant challenges to chemi- 
cal synthesis and thus limit analog design, however. 
Although hydrophobic substituents at the .3,.5 and 3’ posi- 
tions are required for high-affinity binding to the ‘I‘R, 
the iodine substitucnts of T3 are susceptible to reductive 
deiodination, which places restrictions on the types of 
reagents that can be used after the iodines atoms are 
Research Paper An agonist ligand for the thyroid hormone receptor Chiellini et a/. 301 
Figure 2 
/ 
2-isopropyl amsole 
Br 
3 
(b) OH ?CH3 ?CH3 
& Br 
4 
tiH0 
5 
(690/o) BBr,lDCM 
GC-1 8 
I 
Chemistry & Biology 
Synthetic route used for the preparation of GC-1. (a) Synthesis of 3. (b) Synthesis of 5. (c) Synthesis of GC-1 from 3 and 5. isolated yields are 
indicated in parentheses. 
installed. In addition, formation of biaryl ethers remains 
a significant problem in organic synthesis and the biaryl- 
ether linkage in T,j is a particularly difficult one to form 
because of the steric interactions that result from the 3.5 
substituents on the aromatic ring bearing the alanine 
sidechain. -Motivated by these svnthetic considerations, 
we designed the compound GC-1 (Figure 1) which is a 
shape mimic of ‘rj that contains all the essential molecu- 
lar recognition components to insure reasonable affinity 
for the TR. The structural differences between GC-1 
and T3 are: firstly, replacement of the 3,5,3’-iodo groups 
with chemically inert methyl and isopropyl substituents; 
secondly, replacement of the biaryl-ether linkage with a 
mcthylene linkage; and thirdly, replacement of the 
amino-acid substituent at the 1 position with an oxy- 
acetic acid substitucnt. Thus, GC-1 satisfies all the 
essential design criteria of a thyromimetic agent and can 
be synthesized using a convergent route that is amenable 
to analog production. 
Ligand synthesis 
The chemical synthesis of GC-1 is outlined in Figure 2. 
The two aryl halves of GC-1 are constructed first: 
Z-isopropyl anisole [19] is brominated giving bromide 3, 
and 4-bromo-3.5dimethyl phenol is methylated and 
formylated to provide the aldehyde 5. Bromide 3 and 
aldehyde 5 are then coupled via the addition of lithiated 
3 to aldehyde 5 to gi\-e the biar?l alcohol 6. ‘I’his C-C 
bond-forming coupling reaction proceeds in \.cry good 
overall yield and \\\e suspect that this process will be far 
more tolerant to different substituents than the analogous 
hiar>-l-ether-forming reactions. Hydrogenolysis of alcohol 
6 provides the his-anisole 7. which can then be dcmethy- 
lated to the his-phenol 8 using boron tribromidc. 
The final step of the synthesis in\ol\,es mono-alkylation 
of 8 with an a-haloacetate deri\.ative and wc expected that 
this alkylation would proceed selecti\-ely to fawr the 
desired 1-alkylated product o\~er the 4’-alkylated product. 
The 4’-hydroxyl is more sterically hindered than the 
I-hydroxyl because of the neighboring isopropyl sub- 
stituent, and alkylations on similar bis-phenol compounds 
were reported to proceed Lvith such selecti\-it)- [ 1.51. Ilnfor- 
tunatel\- \ve were unable to find conditions that led to 
selective alkylation and this reaction al\vavs Icd to a 
mixture of both l- and 4’-alkylated product. as 11 ell as the 
his-alkylated product. The best conditions for the alkyla- 
tion reaction involved the use of the sterically hindered 
a-chloro t-butylacetate providing GC-1 in 28% isolated 
yield after basic hydrolysis of the t-butvl ester. 
Ligand binding to TRa and TRP 
The binding affinity of GC-1 to TRs was measured using 
a radioligand-displacement assay. Purified human TRa, 
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Competition radioligand displacement assay of ligand affinity for 
human TRP, (a) and human TRc+ (b). A fixed concentration of [12511T3 
was used as the radioligand with the indicated range of concentrations 
of nonradioactive competitor ligand (x-axis). The competition data were 
fit to the equations of Swillens [22] using the GraphPad Prism 
computer program. 
and TRP, were analyzed independently using a fixed 
concentration of [12sI]T, in the presence of a range of 
concentrations of GC-1. GC-1 bound to TRP, with 
approximately the same affinity as T, (Figure 3a), 
whereas GC-1 bound to TRa, with approximately 
0.1 times the affinity of T, (Figure 3b). Tj binds to both 
TRa, and TRP, with similar affinities, with an apparent 
equilibrium dissociation constant (K,,) of 58 pY1 for 
hTRa and 81 pM for hTRP (Table 1). For GC-1, the I(, 
is 67 pM for TRP, and 440 pM for TRa, (Table 1). 
As a comparison, the iodine-free ligand 3,5dimethyl- 
3’-isopropyl-I,-thyronine (DIMIT) was also tested for 
binding to TRa, and TRP, using this assay. DIMIT was 
found to bind both TRs with an affinity approximately 
0.01 times that of T, (Figures 3a,b). In addition to the 
weaker affinity, DIMIT showed no difference in affinity 
between TRa, and TRP,; the K, values for DIMIT- 
TRcx, and DIMIT-TR& were both 10 nM (Table 1). 
Table 1 
Binding affinity of hTRcr, and hTR& for T,, GC-1 and DIMIT. 
K, 1 SE (PM) 
Ligand hTRcL, hTRP, KJTRa,)/Ko(TRP,) 
T, 58+ 12 81 +12 0.7 
GC-1 440f 120 67 +4 6.6 
DIMIT 9700 + 1500 9800 k 1700 1.0 
The K, and standard error (SE) values were calculated by fitting the 
competition data in Figure 3 to the equations of Swillens [22] using 
the GraphPad prism computer program. 
Ligand activation of transcription 
The ligand activation properties of GC-1 were analyzed in 
mammalian cells through the use of a reporter-gene assay. 
GC-1 was first tested in cultured rat pituitary GC cells that 
endogenously express TR, with TR& being the predomi- 
nant isoform [ZO]. These cells were transfected with a 
reporter plasmid that contained two copies of a TRE, each 
with two TR-binding half sites oriented as direct repeats 
separated by four nucleotides (DR4) driving transcription 
of the chloramphenicol acetyl transferase (CAT) gene, and 
were treated with various concentrations of GC-1 or T,3. On 
the basis of CAT activity, GC-1 was found co be a full TR 
agonist with a dose-dependent potency similar to that of T, 
(Figure 4). \I:e next asked whether the TR& selectivity 
apparent in the in c&-o binding experiments would also be 
seen in a cellular transactivation experiment. For this 
experiment, we used HeLa cells. which do not express sig- 
nificant levels of endogenous TRs. HeLa cells were trans- 
fected with either TRa, or TRB, expression plasmids along 
with a TRE-luciferase reporter plasmid and treated with 
various concentrations of GC-1 or T,. Six different activa- 
tion experiments were performed for TRa, and TR(3, and 
the mean values of the data f standard deviation were ana- 
lyzed. The results indicate that, with TRP,, GC-1 is a full 
agonist with an ECS,, (concentration of ligand required for 
one-half maximum activation) that is approximately 
five times greater than that of T, (Figure Sa), whereas with 
TRa,, GC-1 is a full agonist with an ECS,, that is approxi- 
mately 100 times greater than that of T, (Figure Sb). Thus, 
GC-1 is a selective ligand for TRfi, over TRcx, in both 
receptor-binding and ligand-activation functions. 
Discussion 
The studies reported here reflect our initial efforts to 
develop ligands that have TR subtype selectivity in their 
binding and actions. There are, however, inherent syn- 
thetic difficulties in developing structuralI>- diverse col- 
lections of thyromimetic analogs based on the structure 
of T,. The three iodine atoms of T, are sensitive to deio- 
dination, and, as a result of steric bulk and electron with- 
drawal, they limit substitution at certain positions in the 
aromatic rings. In addition, the biaryl-ether linkage 
between the aromatic rings poses difficulties because 
biaryl-ether-forming reactions are not generally robust 
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Ligand activation of a TRE-driven reporter gene in GC cells. The 
chloramphenicol acetyltransferase gene was used as the reporter and 
T, and GC-1 were used as ligands. GC cells express endogenous TRs 
with TRP, as the predominant isoform. 
and the linkage in thyroid hormone is severely stericall) 
hindered by the two iodine atoms at the 3 and 5 posi- 
tions. Thus, it soon became apparent to us that a new 
thyronine scaffold that had the same basic biological 
properties of T, but was more synthetically accessible 
would be highly desirable. 
The X-ray crystallographic structure of the T,?-TR 
complex reveals a unique internal binding mode for the 
hormone and indicates that there is a very tight fit 
between the hormone and LBD [7]. This suggested that 
an effective thyromimetic must at least be a close mimic of 
T,? in terms of overall molecular shape. Drawing on struc- 
ture-activity relations for thyroid hormone analogs, we 
designed GC-1 to be a halogen-free thyromimetic. The 
key features of GC-1 include the replacement of all iodine 
atoms with methyl and isopropyl groups, replacement of 
the biaryl-ether linkage with a methylene linkage, and 
replacement of the amino-acid sidechain with an oxyacetic- 
acid sidechain. We envisioned that these changes would 
solve the major synthetic problems outlined above and that 
GC-1 would be a versatile starting point for the design and 
synthesis of structurally diverse thyromimetic ligands. 
lOL- “’ ..el~__. u-1 , o-” , o-lo , o-9 , o-E , o-7 1 o-6 , o-5 
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TR subtype selectivity measured by ligand activation of a TRE-driven 
reporter gene in HeLa cells. HeLa cells were transfected with 
expression plasmids for either TRP, (a) or TRa, (b) and a reporter 
plasmid containing a TRE-driven luciferase gene. The doubly 
transfected cells were treated with the indicated range of 
concentrations of either T, or GC-1. Transcriptional activation was 
measured by bioluminescence mediated by luciferase. Data are mean 
values f standard deviation from six separate experiments. 
step, addition reactions to the carbon bridge could be per- 
formed, and different ring substituents could be included. GC-1 was synthesized by a convergent synthetic route 
wherein the key step is an efficient aldehyde addition 
reaction that connects the two aryl rings. The only prob- 
lematic step encountered in the process is the final 
alkylation procedure of bis-phenol 8, which does not 
proceed with the desired selectivity. This problem can be 
remedied by differentiating the two phenols early in the 
route with the appropriate protecting groups. The syn- 
thetic route is adaptable to analog design. For example, 
different alkylation reagents could be used in the final 
We were surprised to find that GC-1 has a remarkably high 
affinity for the TR. The ligand binds to TRB, with the 
same affinity as T, and binds to TRa, with tenfold lower 
affinity. The high affinity of GC-1 is somewhat surprising 
because the analog DIRIIT, which contains the 3,5- 
dimethyl-3’-isopropyl ring pattern, binds to the TR with 
only 0.01 the affinity of T,. This suggests that one or both 
of the other two changes in GC-1, namely the methylene 
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linkage and/or the oxyacetic-acid sidechain, confers higher 
affinit>- than the thyronine structure, and therefore compen- 
sates for the deleterious iodine replacements. The methyl- 
ene bridge analog of T, has been made and it shows a 
modest twofold increase in affinity compared to T, [ 17,181. 
It is therefore likely that the oxvacetic-acid sidechain is the 
group that is responsible for most of the affinity compensa- 
tion in GC-1, but unequivocal assignment will only be pos- 
sible after the appropriate T, analogs are made and tested. 
A similar apparent high TR affinity has been reported for 
the halogen-free thyromimetic 2 (Figure l), although crude 
nuclear extract rather than purified TR was used in those 
experiments [15]. 
dimethyl formamide (DMF) was stirred for 20 h at room temperature. The 
reaction mixture was diluted with 300 ml of ether and washed with 
250 ml of water and 5 x 100 ml of brine. The organic portion was dried 
(MgSO,), filtered, and evaporated to give an oil, which was purified by 
flash column chromatography (silica gel, 9O:lO hexanejethyl acetate) to 
give the pure product (12.5 g, 82.1 mmol, 93%); ‘H NMR (CDCI, 300 
MHz) F 1.21 (d, 6H, J=6.9 Hz), 3.32 (heptet, lH, J =6.9 Hz), 3.83 
(s,3H), 6.85 (d,lH, J=8.1 Hz), 6.93 (t,lH, J=7.5Hz), 7.17 (t,lH, 
J = 8.1 Hz), 7.21 (d, 1 H, J = 7.5 Hz). ‘% NMR (CDCI, 300 MHz) F 22.8, 
26.9,55.4, 110.5, 120.7, 126.1, 126.7, 137.2, 156.9. 
4-Bromo-2-isopropyl ankole (3). To a suspension of KBr (18.8 g, 
157.7 mmol) in 400 ml of methylene chloride at 0°C were added 
18-Crown-6 (2.08 g, 7.88 mmol), 3chloroperoxy benzoic acid (27.2 g, 
157.7 mmol) and 2-isopropyl anisole (12.0 g, 78.8 mmol). After stirring 
for 3 h at OX, the reaction mixture was poured into ice water (500 ml), 
and stirred 0.5 h. The organic layer was separated, washed with sat. 
The finding that GC-1 is selectiv-e for TRB over TRa was 
NaHCO, solution (400ml) anb then water (300 ml), and dried 
also surprising. This TRP selectivity is seen, not only in 
(MgSO,). The solvent was evaporated to give an oil, which was purified 
by flash column chromatography (silica gel, 98:2 hexane/ethyl acetate) 
binding exDeriments, but also in dose-resnonse cellular to give 13 g (56.7 mmol, 72%) of 3 as an oil; ‘H NMR (CDCI, 
II L 
transactivation experiments. The thyromimetic 2 (Figure 1) 306MHz) S 1.2 (d, 6H, J = 6.9 Hz), 3.27 (heptet, 1 H, J = 6.9 Hz), 3.i 
also shows selectivity for TRP in cellular transactiration (s,3H), 6.7 (d, lH, J=8.4Hz), 7.23 (d, lH, J=2.4Hz), 7.26 (dd, lH, 
assays [l(i]. Thus. these studies indicate that synthetic 
J = 2.4, 8.4 Hz). ‘3C NMR (CDCI, 300 MHz) 6 22.6, 26.9, 55.7, 112.2, 
113.2. 129.3. 139.6. 156.1. HR-MS. calc’d for C,,H,,OBr. 230.0129: 
ligands can have the property of selectivity for binding and 
\” IS 
found, 230.0126. 
acti\-ation of the different TR isoforms whereas thvroid 
hormone shows no such selectivity. These ligands map be 4-Bromo-3,5-dimethyl anisole (4). A mixture of 4-bromo-3,5-dimethyl 
useful for animal studies aimed at understanding the rela- 
phenol (25.0 g, 124.3 mmol), methyl iodide (35.3 g, 248.6 mmol), and 
tive roles of TRa and TR/3 in mediating the actions of 
potassium carbonate (34.4 g, 248.6 mmol) in 62.5 ml of DMF was 
stirred for 2 h at room temperature. The reaction mixture was diluted 
thyroid hormones, and for human studies to determine if with 300 ml of ether and washed with 250 ml of water and 5 x 100 ml 
use of selective compounds can retain beneficial actions of of brine. The organic portion was dried (MgSO,), filtered, and evapo- 
thyroid hormones with decreased deleterious actions. 
rated to give an oil, which was purified by flash column chromatography 
(silica gel, 9O:lO hexane/ethyl acetate) to give 4 (26 g, 120.8 mmol, 
Significance 
970/o); ‘H NMR (CDCI, 300 MHz) F 2.37 (s, 6H), 3.74 (s, 3H), 6.63 
(s, 2H). 13C NMR (CDCI, 300 MHz) F 24.2, 55.4, 113.9, 118.4, 139.2, 
We have designed and synthesized a thyroid hormone 158.1. HR-MS, calc’d for C,H,, OBr, 215.9973; found, 215.9979. 
receptor (TR) ligand representative of a new class of thy- 
romimetics that have several synthetic advantages over 
2,6-Dimethyl-4-metboxy benzaldehyde (5). To 4 (20 g, 93.0 mmol) in 
traditional thyromimetics. By changing the biaryl-ether 
500 ml of tetrahydrofuran at -78°C was added 120 ml of teti-butyl- 
lithium (1.7 M in pentane). The reaction mixture was stirred for 30 min at 
linkatie uresent in thvroid hormone to a methvlene -78°C and then DMF (136.0 g, 186.0 mmol) was added. The reaction 
the analogous biaryl ether coupling reactions suggesting 
Y 1 
linkage we are able to use an efficient C-C bond forming 
that a greater variety of thyromimetic structural variants 
will be accessible through this synthetic strategy. The 
reaction in the key biaryl-coupling step. This process is 
lead compound GC-1 has interesting and potentially 
useful thyromimetic properties. GC-1 is a high affinity 
likely to be more tolerant to different substituents than 
ligand for the TR and shows subtype selectivity for TRP 
over TRcx in both receptor-binding and l&and-activation 
functions. Thyroid hormone T, does not show such 
selectivity and binds both TRs with the same affinity. 
This TRP selectivity property of GC-1 suggests that GC-1 
will be a useful chemical probe to study the physiological 
role of the different TR subtypes and isoforms in vivo. 
purified by flash column chromatography (silica gel, 9O:lO hexane/ethyl 
acetate) to yield 5 (9.50 g, 57.8 mmol, 62%) as a white solid; ‘H NMR 
mixture was stirred for 1 h at -78°C and for 1.5 h at room temperature, 
(CDCI, 300 MHz) F 2.61 (s, 6H), 3.83 (s, 3H), 6.6 (s, 2H), 10.5 (s, 1 H). 
13CNMR (CDCI,300MHz): 6 21.3, 55.4, 114.8, 126.1, 144.7, 162.9, 
diluted with 300 ml of ether, and washed with 300 ml of water, acidified 
191.3. HR-MS, calc’d for C,,H,,O,, 164.0837; found, 164.0832. 
with 1 N HCI, and 5 x 100 ml of brine. The organic portion was dried 
(MgSO,), filtered, and evaporated to give the crude product, which was 
3,5-Dimethyl-4-(3’-~sopropyl-4’-methoxybenzylhydroxy) anisole (6). To 3 
(12 g, 52.4 mmol) in 300ml of tetrahydrofuran at -78% was added 
68 ml of tert-butyllithium (1.7 M in pentane). The reaction mixture was 
stirred for 10 min at -78% and then 5 (8.6 g, 52.4 mmol) was added. 
The reaction mixture was stirred for 1 h at -78’C and for 1.5 h at room 
temperature, diluted with 150 ml of ether, washed with 150 ml of water, 
acidified with 1 N HCI, and 5 x 50 ml of brine. The organic portion was 
dried (MgSO,), filtered, and evaporated to give the crude product, 
which was purified by flash column chromatography (silica gel, 
95:5 hexane/ethyl acetate) to yield 6 (12 g, 38.2 mmol, 73%) as an oil; 
‘H NMR (CDCI, 300 MHz) 6 1.18 (dd, 6H, J = 6.6, 6.9 Hz), 2.25 (s, 
6H), 3.29 (heptet, lH, J =6.9 Hz), 3.79 (s, 6H), 6.25 (s, lH), 6.58 (s, 
2H), 6.73 (d, lH, J=8.7Hz), 6.89 (dd, lH, J=2.1, 8.7Hz), 7.23 (d, 
1 H, J = 2.1 Hz).‘~C NMR (CDCI, 300 MHz): 6 21.2, 23.8, 27.1, 55.3, 
55.7, 71.1, 110.1, 114.5, 123.7, 132.2, 135.1, 136.8, 138.9, 155.7, 
158.5. HR-MS, calc’d for CZoH2s03, 314.1882; found, 314.1871. 
Materials and methods 
Synthesis 
2-Isopropyl anisole was prepared using the familiar Williamson-type con- 
densation between an alcohol and a halide [191. Briefly, a mixture of 
2isopropylphenol (12.0 g, 88.1 mmol), methyl iodide (25.0 g, 
176.2 mmol), and potassium carbonate (24.3 g, 176.2 mmol) in 44 ml of 
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3,5-D/methyl-4-(3’.isopropy/+methoxybenzyl) an&o/e (7). A solution 
of 6 (2.0 g, 6.36 mmol) in 22 ml of 9% (v/v) AcOH in EtOH containing 
10% Pd/C (200 mg) was hydrogenated at 1 atm at room temperature. 
When hydrogen uptake was complete (12 h), the catalyst was flltered 
off and the filtrate was diluted with 200 ml of ether, washed with sat. 
NaHCO, solution (3 x 50 ml), water (150 ml) and brine (3 x 50 ml). 
The solvent was evaporated to yield 1.5 g (5.03 mmol, 79%) of 7 as an 
oil. This material was used in the next step without further purification; 
‘H NMR (CDCI, 300 MHz) 6 1 .16 (d, 6H, J = 6.9 Hz), 2.22 (s, 6H), 
3.26 (heptet, IH, J=6.9 Hz), 3.77 (s, 3H), 3.79 (s, 3H), 3.91 (s, 2H), 
6.62 (s, 2H), 6.65-6.70 (m, 2H), 6.95 (d, IH, J=2.1 Hz). 13C NMR 
(CDCI,300MHz): F 20.7, 22.9, 27.1, 33.9, 55.8, 56.2, 110.4, 113.5, 
125.2, 126.1, 129.9, 132.1, 136.9, 138.6, 155.1, 157.7. HR-MS, 
calc’d for C,,H,,02, 298.1933; found, 298.1931. 
3,5-Dimethyl-4-(4’-hydroxy-3’.isopropylbenzyl) phenol (8). To 7 (1.3 g, 
4.35 mmol) in 75 ml of methylene chloride at -78’C was added 44 ml of 
boron tribromide (1 .O M in methylene chloride). The reaction mixture was 
stirred for 30 min at -78°C and for 10 h at room temperature. The reac- 
tion mixture was washed with water (2 x 100 ml), dried (MgSO,), and 
evaporated to give crude product (1.5 g). Punfication using flash column 
chromatography (silica gel, 80:20 hexane/ethyl acetate) gave 8 (812 mg, 
3.00 mmol, 69%); ‘H NMR (CDCI, 300 MHz) 6 1.2 (d, 6H, J = 6.9 Hz), 
2.18 (s, 6H), 3.15 (heptet, 1 H, J = 6.9 Hz), 3.89 (s, 2H), 6.57 (m, 4H), 
6.91 (s, 1H). 13CNMR (CDCI, 300MHz): 6 20.5, 22.7, 27.3, 33.8, 
114.9, 115.3, 126.7, 129.9, 132.5, 134.7, 138.9, 150.9, 153.5. 
HR-MS, calc’d for C,*H,,O,, 270.1618; found, 270.1620. 
13,5-Dimethyl-4-(4’-hydroxy-3’-,sopropy/benzy/j phenoxyl acetic at/d 
(GC-1). To cesium carbonate (3.01 g, 9.24 mmol) and 8 (500 mg, 
1.85 mmol) in 37.5 ml of 37% (v/v) DMF in tetrahydrofuran at -25°C 
was added tert-butylchloroacetate (278.6 mg, 1.85 mmol). The reaction 
mixture was stirred for 1 h at -25°C and for 30 min at room temperature, 
poured into 100 ml of cold 1 N HCI, and extracted wtth ethyl acetate 
(3 x 150 ml). The combined organic portlons were dried (MgSO,) and 
evaporated to yield 700 mg of crude, which was purified using flash 
column chromatography (silica gel, 9O:lO hexane/ethyl acetate) to yield 
the product (250 mg), used directly in the following reaction; ‘H NMR 
(CDCI, 300 MHz) 6 1.2 (d, 6H, J = 6.9 Hz), 1.5 (s, SH), 2.17 (s, 6H), 
3.16 (heptet, lH, J=6.9 Hz), 3.88 (s, 2H), 4.50 (s, 2H), 6.55-6.58 
(m, 2H), 6.60 (s, 2H), 6.90 (s, 1H). To the above ester (200 mg, 
0.520 mmol) in 4 ml of methanol was added 2.6 ml of 1 N NaOH. The 
reaction mixture was stlrred for 1 h at room temperature, acidified with 
3 ml of 2 N HCI, and extracted with ethyl acetate (2 x 25 ml). The com- 
bined organic portions were dried (MgSO,) and evaporated to give 
GC-1 (1 70 mg, 0.518 mmol, 28%); ‘H NMR (CD,OD 300 MHz) 6 1 .15 
(d, 6H, J =6.6 Hz), 2.18 (s, 6H), 3.21 (heptet, lH, J=6.6 Hz), 3.86 
(s, 2H), 4.40 (s, 2H), 6.49-6.62 (m, 2H), 6.65 (s, 2H), 6.84 (s, 1H). 
13C NMR (CD,OD300 MHz): 6 20.8, 23.0, 27.6, 34.4, 68.3, 115.2, 
115.6, 126.0, 126.4, 126.5, 131.6, 135.6, 139.1, 152.8, 157.0, 177.9. 
HR-MS, calc’d for C20H2404, 328.1675; found, 328.1679. 
Thyroid hormone receptor ligand binding assays 
Full-length hTRa, and hTRP, were produced using the TNT coupled 
reticulocyte lysate system (Promega). The llgand binding domains of 
hTRcc, and hTR& were expressed In Escherichia co/i and purified to 
greater than 95% homogeneity as described previously [21]. Competi- 
tlon assays for binding of unlabelled T,, DIMIT, and GC-1 were per- 
formed using 1 nM [1251]T3 in gel filtration blnding assays as described 
1211. The K, and standard error (SE) values were calculated by fitting 
the competition data to the equations of Swlllens [221 using the Graph- 
Pad Prism computer program (GraphPad Software, Inc.). 
Cell culture, transfections and reporter gene assays 
GC and HeLa cells were maIntaIned and subcultured in DME H-21, 
4.5 g/l Glucose media containing 10% newborn bovine serum, 2 mM 
glutamlne, 50 units/ml penicillin, and 50 pg/ml streptomycin. Transfec- 
tion procedures were described previously [23,24]. Briefly, cells were 
collected and resuspended In Dulbecco’s PBS (0.5 ml/transfection) 
containing 0.1% dextrose, 10 fig/ml blobrene, and mixed with 0.5 Kg 
of the appropriate TR expression vector and 10 Kg of the reporter 
plasmld. The TR expression vector contained either the full length 
human TRP, or human TRc(, under the control of the cytomegalovirus 
promoter, CMVTRP, and CMVTRa,, respectively. The reporter 
plasmid contalned a synthetic TR response element (DR-4) containing 
two copies of a direct repeat spaced by four nucleotides (AGGTCA- 
cagg-AGGTCA) cloned immediately upstream of a minimal (-32/+45) 
thymidine kinase (tk) promoter linked to either chloramphenicol acetyl 
transferase (CAT) or luciferase coding sequences. Cells (2.0 x 1 O7 or 
0.8 x 1 07, for GC and HeLa cells, respectively) were electroporated 
using a Blo-Rad gene pulser at 330 (GC ceils) or 350V (HeLa cells) 
and 960 mlcrofarads, pooled In growth medium (DME H-21 with 10% 
charcoal-treated, hormone-stripped, newborn bovine serum), plated in 
6-well dishes, and treated with either vehicle (ethanol), hormone (T,), 
or GC-1. T, and GC-1 were used at increasing concentrations, 
1 O~‘O-1 0m7 M and 1 Of”-1 O-5 M, respectively (for CAT assays, ligand 
concentrations of 1 O-“-l 0e7 M and 1 Ok”-1 O-6 M were used for T, 
and GC-1, respectively). After incubation for 24 h at 37OC cells were 
detached with 1 ml of calcium-magnesium-free PBS, 1 mM EDTA, pre- 
warmed at 37%, and transferred to 1.5 ml Eppendorf tubes. Cells 
were pelleted by centrifugation in a microfuge for 1 min at room tem- 
perature (RT). The supernatants were aspirated and the pellets were 
lysed by addition of 120 pl of Tris-Cl 0.25 M pH 7.6, 0.1% Triton. 
After resuspension by vortexing for 5-l 0 s, the lysates were pelleted 
by centrifugation In a microfuge for 5 min at RT. Cellular lysates 
(75 ~1) were then assayed for CAT as previously described [25]. For 
luciferase activity measurements, 100 ~1 of the cellular lysate was 
added to 300 PI of 25 mM glycylglycine pH 7.8, 15 mM MgSO,, 
4 mM EGTA, 15 mM potassium phosphate pH 7.8, 1 mM DTT, 
2 mM ATP, 0.2 mM Luciferin [26]. The light output was measured for 
10 s at RT with a luminometer (Analytical Luminescence Laboratory, 
MONOLIGHTR 1500). 
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